Sign Out
GLAKAY should be administered to patients who have been diagnosed as having osteoporosis and have a decrease in bone mass and pain in accordance with the criteria prepared by the General Study Group on Prevention and Treatment of Senile Osteoporosis (general criteria based on whether it is or not) of the Ministry of Health and Welfare (MHW) of Japan, etc.
Rash, redness, pruritus or other sympotoms may occur.
In the event of such symptoms, treatment should be discontinued.
Use in Children: The safety in children has not been established (no clinical experience).
Use in the Elderly: As GLAKAY is usually administered to the elderly for a long period of time, their condition should be carefully observed during administration.
Continue with Google